Key result
In older adults with dementia, exposure to cholinesterase inhibitors was associated with a lower risk of subsequently receiving a bladder anticholinergic medication (adjusted HR 0.79) compared to non-users.
Why the study?
Prescribing cascades are a recognized source of inappropriate prescribing for older adults with dementia.
Does the use of inciting medications (cholinesterase inhibitors, metoclopramide, calcium channel blockers) increase the risk of prescribing cascades in older adults with dementia?
Cohort (n=28,953)
Does the use of inciting medications (cholinesterase inhibitors, metoclopramide, calcium channel blockers) increase the risk of prescribing cascades in older adults with dementia?
Hazard Ratio: 0.79 (95% CI 0.68–0.92)
Absolute Event Rate: 6.3% vs 6.3%
In older adults with dementia, the use of cholinesterase inhibitors or calcium channel blockers did not increase the risk of subsequent prescribing of bladder anticholinergics or diuretics, respectively, though these cascades were more common in women.
Does not support cholinesterase inhibitor prescribing cascade in dementia; observational design leaves causality and confounding open.
Background Prescribing cascades are a source of inappropriate prescribing for older adults with dementia. We aimed to study three prescribing cascades in older Nova Scotians with dementia using administrative databases. Methods Cohort entry for Nova Scotia Seniors’ Pharmacare Program beneficiaries was the date of dementia diagnosis. Prescription drug dispensing data was extracted for inciting medication and second treatment (cholinesterase inhibitor and bladder anticholinergic, metoclopramide and Parkinson’s disease medication, or calcium channel blocker (CCB) and diuretic) over the six-year period April 1, 2009 to March 31, 2015. In three separate analyses, dispensing an inciting medication signaled a look back of 365 days from the date of first dispensing to confirm that the second treatment was started after the inciting medication. The prescribing cascade was considered when the second treatment was started within 180 days of the inciting treatment. Sex differences in the prescribing cascade were tested using t-tests or chi square tests as appropriate. Both univariate (unadjusted) and multivariate (adjusted) logistic regression (adjusted for age, rurality, and sex) and Cox proportional hazards regression was used to identify risk factors for the prescribing cascade. Results From March 1, 2005 to March 31, 2015, 28,953 Nova Scotia Seniors' Pharmacare beneficiaries with dementia (NSSPBD) were identified. There were 60 cases of bladder anticholinergics following cholinesterase inhibitors, 11 cases of Parkinson’s disease medication following metoclopramide, and 289 cases of a diuretic following CCB in the cohort. Regression analysis demonstrated that risk of bladder anticholinergics following cholinesterase inhibitors and diuretics following CCBs were associated with female sex. Cox regression suggested that bladder anticholinergics were less often used by those on cholinesterase inhibitors and did not identify CCB use as leading more frequently to diuretic use. Conclusions The combination of diuretics following CCB was the most common prescribing cascade and bladder anticholinergics following cholinesterase inhibitors the second most common. However, exposure to the inciting medications did not increase risk of exposure to the second treatments. Combinations of bladder anticholinergics following cholinesterase inhibitors and diuretics following CCBs were more common for women raising concern that women may be at increased risk of these prescribing cascades.
No takes yet. Share an insight, caveat, or question.
Trenaman et al. (2021) conducted a cohort in Dementia (n=28,953). Cholinesterase inhibitors vs. No cholinesterase inhibitor was evaluated on Newly dispensed bladder anticholinergic (HR 0.79, 95% CI 0.68-0.92). In older adults with dementia, exposure to cholinesterase inhibitors was associated with a lower risk of subsequently receiving a bladder anticholinergic medication (adjusted HR 0.79) compared to non-users.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: